triaziquone has been researched along with Lymphangioendothelioma, Malignant in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (100.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Adler, S; Case, RW; Helm, F; Holtermann, OA; Klein, E; Milgrom, H; Murphy, GP; Prior, RL; Rosner, D; Stoll, HL | 1 |
1 review(s) available for triaziquone and Lymphangioendothelioma, Malignant
Article | Year |
---|---|
Immunologic approaches to the management of primary and secondary tumors involving the skin and soft tissues: review of a ten-year program.
Topics: Antigens, Bacterial; Antigens, Fungal; Antigens, Viral; Breast Neoplasms; Carcinoma, Basal Cell; Female; Humans; Hypersensitivity, Delayed; Immunotherapy; Lymphangiosarcoma; Lymphoma, Large B-Cell, Diffuse; Melanoma; Neoplasms, Multiple Primary; Nitrobenzenes; Precancerous Conditions; Skin Neoplasms; Skin Tests; Triaziquone; Vulvar Neoplasms | 1975 |